NASDAQ:ISRG - Intuitive Surgical Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$561.18 +4.71 (+0.85 %)
(As of 09/21/2018 03:30 AM ET)
Previous Close$556.47
Today's Range$556.83 - $561.97
52-Week Range$337.80 - $572.96
Volume386,700 shs
Average Volume782,375 shs
Market Capitalization$64.25 billion
P/E Ratio77.98
Dividend YieldN/A
Intuitive Surgical logoIntuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories. The company's da Vinci surgical System translates a surgeon's natural hand movements, which are performed on instrument controls at a console into corresponding micro-movements of instruments positioned inside the patient through small incisions or ports. Its da Vinci surgical system include surgeon's consoles, patient-side carts, 3-D vision systems, da Vinci skills simulators, da Vinci Xi integrated table motions, and Firefly fluorescence imaging products that enable surgeons to perform various surgical procedures, including gynecologic, urologic, general, cardiothoracic, and head and neck surgical procedures. The company also manufactures EndoWrist instruments that include forceps, scissors, electrocautery, scalpels, and other surgical tools, which incorporate wrist joints for natural dexterity for various surgical procedures. In addition, it offers da Vinci Single-Site instruments and accessories that allow surgical systems to work through a single incision; and EndoWrist One vessel sealers that are wristed single-use instruments intended for bipolar coagulation and mechanical transection of vessels up to 7 mm in diameter and tissue bundles that fit in the jaws of the instrument. Further, the company provides EndoWrist stapler, a wristed stapling instrument intended for resection, transection, and/or creation of anastomoses, as well as sells various accessories, including replacement 3-D stereo endoscopes, camera heads, light guides, and other items that facilitate use of the da Vinci system, as well as sterile drapes for ensuring a sterile field during surgery. Intuitive Surgical, Inc. markets its products directly and through distributors in the United States, Europe, Asia, and internationally. The company was founded in 1995 and is headquartered in Sunnyvale, California.

Receive ISRG News and Ratings via Email

Sign-up to receive the latest news and ratings for ISRG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical appliances & supplies
Sub-IndustryHealth Care Equipment


Debt-to-Equity RatioN/A
Current Ratio5.98
Quick Ratio5.48


Trailing P/E Ratio77.98
Forward P/E Ratio60.28
P/E Growth4.13

Sales & Book Value

Annual Sales$3.13 billion
Price / Sales20.40
Cash Flow$8.4911 per share
Price / Cash66.09
Book Value$42.19 per share
Price / Book13.30


EPS (Most Recent Fiscal Year)$7.19
Net Income$660 million
Net Margins23.20%
Return on Equity20.56%
Return on Assets17.55%


Outstanding Shares113,750,000
Market Cap$64.25 billion

Intuitive Surgical (NASDAQ:ISRG) Frequently Asked Questions

What is Intuitive Surgical's stock symbol?

Intuitive Surgical trades on the NASDAQ under the ticker symbol "ISRG."

When did Intuitive Surgical's stock split? How did Intuitive Surgical's stock split work?

Intuitive Surgical shares split before market open on Friday, October 6th 2017. The 3-1 split was announced on Friday, August 11th 2017. The newly issued shares were payable to shareholders after the closing bell on Thursday, October 5th 2017. An investor that had 100 shares of Intuitive Surgical stock prior to the split would have 300 shares after the split.

How were Intuitive Surgical's earnings last quarter?

Intuitive Surgical, Inc. (NASDAQ:ISRG) issued its quarterly earnings data on Thursday, July, 19th. The medical equipment provider reported $2.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.02 by $0.74. The medical equipment provider had revenue of $909.30 million for the quarter, compared to the consensus estimate of $877.43 million. Intuitive Surgical had a net margin of 23.20% and a return on equity of 20.56%. The business's revenue for the quarter was up 19.8% on a year-over-year basis. During the same period in the previous year, the business posted $5.95 earnings per share. View Intuitive Surgical's Earnings History.

When is Intuitive Surgical's next earnings date?

Intuitive Surgical is scheduled to release their next quarterly earnings announcement on Thursday, October, 18th 2018. View Earnings Estimates for Intuitive Surgical.

What price target have analysts set for ISRG?

18 brokerages have issued 12 month price targets for Intuitive Surgical's stock. Their forecasts range from $300.00 to $635.00. On average, they expect Intuitive Surgical's stock price to reach $520.3137 in the next twelve months. This suggests that the stock has a possible downside of 7.3%. View Analyst Price Targets for Intuitive Surgical.

What is the consensus analysts' recommendation for Intuitive Surgical?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intuitive Surgical in the last year. There are currently 1 sell rating, 4 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intuitive Surgical.

What are Wall Street analysts saying about Intuitive Surgical stock?

Here are some recent quotes from research analysts about Intuitive Surgical stock:
  • 1. According to Zacks Investment Research, "Intuitive Surgical outperformed its industry in a year’s time. The company exited the second quarter of 2018 on a favorable note, beating the Zacks Consensus Estimate on both the counts. The company’s flagship da Vinci procedures recorded solid growth. It is a robot-based surgical system for minimally-invasive surgery that reduces the trauma associated with open surgery. A suite of regulatory approvals for the Vessel Sealer Extend, the da Vinci SP Surgical System, and the Sure Form 60 buoys optimism. Solid growth in prostatectomy procedure volumes lent Intuitive Surgical a competitive edge in the broader prostate surgery market. On the flipside, the company expects outside U.S. sales to be a bit lumpy in the quarters ahead. These markets are in early stages of adoption. Intense competition in niche space as well as long sale and purchase order cycles of da Vinci unit has been currently plaguing the company." (7/24/2018)
  • 2. BTIG Research analysts commented, "Surgical reported another sweep this quarter, exceeding consensus expectations on every key metric: procedures, systems, sales, and EPS. The company shipped 220 systems in Q2, well above our 197 units and the Street’s 191 units. As in recent quarters, a significant portion (20%) of these systems were placed under operating leases. We view this as a smart strategy that is helping boost procedure growth. Procedure volume increased ~18% y/y in the quarter, again eclipsing expectations. Instrument segments exceeded consensus estimates too. We think the factors underlying repeated outperformances are likely to continue for some time and there are exciting product catalysts on the way. We remain at Neutral, as shares trade at ~57x NTM EPS, which we think excessive. Still, this stock keeps motoring upwards and may keep doing so as long as this med tech bull market continues." (7/22/2018)
  • 3. Northland Securities analysts commented, "We continue to be DEAD WRONG on the stock. The argument on this stock is now primarily about how much you can stretch valuation. The stock currently trades at ~ 15x forward P/S and ~54x forward P/E. We are not sure in what world these metrics can be sustained. The confluence of 4 factors….a nutty market which has no correlation to fundamentals, lack of any serious competition from the likes of MDT and JNJ, positive f/x contribution due to the weaker dollar, and finally, a lower tax rate due to the recent tax law passed, are yielding higher returns." (7/20/2018)
  • 4. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating on shares of ISRG and raise our price target to $620 from $510. Quarter after quarter, ISRG continues to justify its premium valuation, again significantly beating on all metrics we track, including the top and bottom line. ISRG delivered 18% procedure growth for 2Q18, one of the strongest quarterly procedure growth figures y/y in the last five years, with broad strength across all procedure categories. ISRG raised full-year 2018 procedure growth guidance to 14.5-16.5% from 12-15%. The installed based grew 12% and utilization was up by mid-single digits." (7/20/2018)

Who are some of Intuitive Surgical's key competitors?

Who are Intuitive Surgical's key executives?

Intuitive Surgical's management team includes the folowing people:
  • Dr. Gary S. Guthart, CEO, Pres & Director (Age 52)
  • Mr. Marshall L. Mohr, Sr. VP & CFO (Age 62)
  • Mr. Salvatore J. Brogna, Exec. VP & COO (Age 63)
  • Mr. David J. Rosa, Exec. VP & Chief Commercial Officer (Age 50)
  • Dr. Myriam J. Curet McAdams, Exec. VP & Chief Medical Officer (Age 61)

Has Intuitive Surgical been receiving favorable news coverage?

News stories about ISRG stock have trended somewhat positive on Friday, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Intuitive Surgical earned a news impact score of 0.18 on Accern's scale. They also assigned news headlines about the medical equipment provider an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for Intuitive Surgical.

Who are Intuitive Surgical's major shareholders?

Intuitive Surgical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.69%), FMR LLC (5.83%), Bank of New York Mellon Corp (2.67%), Bank of New York Mellon Corp (2.67%), Edgewood Management LLC (2.16%) and Baillie Gifford & Co. (2.09%). Company insiders that own Intuitive Surgical stock include Alan J Levy, Amal M Johnson, Colin Morales, Craig H Barratt, Curet Myriam, David J Rosa, Gary S Guthart, Jamie Samath, Keith R Leonard, Lonnie M Smith, Mark J Meltzer, Mark J Rubash, Marshall Mohr, Michael A Friedman and Salvatore Brogna. View Institutional Ownership Trends for Intuitive Surgical.

Which institutional investors are selling Intuitive Surgical stock?

ISRG stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., BlackRock Inc., Renaissance Technologies LLC, Assenagon Asset Management S.A., Brown Advisory Inc., Janus Henderson Group PLC, Russell Investments Group Ltd. and Great West Life Assurance Co. Can. Company insiders that have sold Intuitive Surgical company stock in the last year include Alan J Levy, Craig H Barratt, Curet Myriam, David J Rosa, Gary S Guthart, Jamie Samath, Lonnie M Smith, Mark J Meltzer, Mark J Rubash, Marshall Mohr, Michael A Friedman and Salvatore Brogna. View Insider Buying and Selling for Intuitive Surgical.

Which institutional investors are buying Intuitive Surgical stock?

ISRG stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley, Cornerstone Wealth Management LLC, Jennison Associates LLC, Los Angeles Capital Management & Equity Research Inc., Congress Asset Management Co. MA, Partner Fund Management L.P. and Point72 Asset Management L.P.. View Insider Buying and Selling for Intuitive Surgical.

How do I buy shares of Intuitive Surgical?

Shares of ISRG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intuitive Surgical's stock price today?

One share of ISRG stock can currently be purchased for approximately $561.18.

How big of a company is Intuitive Surgical?

Intuitive Surgical has a market capitalization of $64.25 billion and generates $3.13 billion in revenue each year. The medical equipment provider earns $660 million in net income (profit) each year or $7.19 on an earnings per share basis. Intuitive Surgical employs 4,444 workers across the globe.

How can I contact Intuitive Surgical?

Intuitive Surgical's mailing address is 1020 KIFER ROAD, SUNNYVALE CA, 94086. The medical equipment provider can be reached via phone at 408-523-2100 or via email at [email protected]

MarketBeat Community Rating for Intuitive Surgical (NASDAQ ISRG)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  737 (Vote Outperform)
Underperform Votes:  510 (Vote Underperform)
Total Votes:  1,247
MarketBeat's community ratings are surveys of what our community members think about Intuitive Surgical and other stocks. Vote "Outperform" if you believe ISRG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ISRG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/21/2018 by Staff

Featured Article: Tariff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel